HES & EGPA | Expert Webinar 2025: Causes, Symptoms & Treatment Insights скачать в хорошем качестве

HES & EGPA | Expert Webinar 2025: Causes, Symptoms & Treatment Insights

👉Click "more" to jump to questions of your interest. Understand Hypereosinophilic Syndrome (HES) and Eosinophilic Granulomatosis with Polyangiitis (EGPA): causes, common symptoms, and treatment options for managing these rare conditions. With Prof. Florence Roufosse. 👉 Register with us for more expert webinars and resources: www.eosnetwork.org Support us: https://adbrydbw.donorsupport.co/page... ✅Key Questions and Topics Covered: 02:36 Introducing the Eosinophil: nature and origins, behaviour and functions 11:55 Hypereosinophilia and HES: blood and tissue hypereosinophilia 14:24 HES clinical manifestations 15:18 Pathogenesis of hypereosinophilia in HES: two major disease variants and their disease presentations 20:15 Natural disease course in patients with HES 21:54 HES diagnosis: common causes of increased eosinophil count, evidence of eosinophil-mediated organ damage and dysfunction and disease variants investigations 23:18 EGPA clinical presentation: asthma, blood and tissue hypereosinophilia, vasculitis 25:02 EGPA clinical manifestations: eosinophil-mediated and vasculitic complications 25:50 Typical stepwise EGPA progression 26:28 Overlap between EGPA and HES 26:49 Diagnosis of EGPA: comorbid diseases, blood and pulmonary function tests, ENT check, imaging and other tests. 28:27 Treatment of HES and EGPA: corticosteroid and other treatment options 32:00 Targeting the eosinophil: critical role of Interleukin (IL)-5 in eosinophil biology and as therapeutic targets in eosinophil disorders 34:04 Clinical trials for HES with agents targeting the IL-5 pathway - Mepoluzimab, Benralizumab, tapering corticosteroid doses and outcomes: reduction in blood eosinophil count, fatigue 38:17 How eosinophil-targeted treatments fit in nowadays: tapering corticosteroids, eosinophil-depleting treatments 38:51 Clinical trials for EGPA targeting IL-5: MIRRA trial (Mepoluzimab), MANDARA (Benralizumab) - achieving remission, fewer relapses, reduction in eosinophil counts, and glucocorticosteroids sparing 44:56 Take-home messages